Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adulteration meeting set

This article was originally published in The Tan Sheet

Executive Summary

FDA schedules a May 1 public meeting to discuss methods for better predicting and preventing economically motivated adulteration of regulated products. The meeting in College Park, Md., will address what industry is doing and could do to prevent EMA. FDA, the U.S. Pharmacopeia and industry stakeholders are revising analytical testing standards to effectively screen for contaminated heparin, diethylene glycol in glycerin and melamine in infant formula - recent instances of EMA (1"The Tan Sheet" Feb. 16, 2009, p. 16)

You may also be interested in...



U.S. Pharmacopeia Moves Melamine Testing Into The 21st Century

U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis

Formycon And Bioeq Offer Ranibizumab Update

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.

Oxular Sets Out Eye Disease Plans Armed With $37m

The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel